MRK vs OM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Outset Medical exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. Despite a strong current ratio of 6.67 suggesting short-term liquidity, the company suffers from catastrophic long-term price erosion (-99.5% over 5 years) and negative revenue growth. The combination of deep negative profit margins (-68.34%) and consistent insider selling suggests a lack of confidence in a turnaround. While analysts maintain a 'buy' rating with a $9.00 target, the deterministic data points to a high risk of further capital impairment.
Compare Another Pair
Related Comparisons
MRK vs OM: Head-to-Head Comparison
This page compares Merck & Co., Inc. (MRK) and Outset Medical, Inc. (OM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.